BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saxena A. Drug targets for COVID-19 therapeutics: Ongoing global efforts. J Biosci 2020;45:87. [PMID: 32661214 [PMID: 32661214 DOI: 10.1007/s12038-020-00067-w] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 17.5] [Reference Citation Analysis]
Number Citing Articles
1 Goyal M, Tewatia N, Vashisht H, Jain R, Kumar S. Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review. J Infect Public Health 2021;14:910-21. [PMID: 34119845 DOI: 10.1016/j.jiph.2021.04.011] [Reference Citation Analysis]
2 Das G, Das T, Chowdhury N, Chatterjee D, Bagchi A, Ghosh Z. Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19. Genomics 2021;113:1129-40. [PMID: 33189776 DOI: 10.1016/j.ygeno.2020.11.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Shaji D, Yamamoto S, Saito R, Suzuki R, Nakamura S, Kurita N. Proposal of novel natural inhibitors of severe acute respiratory syndrome coronavirus 2 main protease: Molecular docking and ab initio fragment molecular orbital calculations. Biophys Chem 2021;275:106608. [PMID: 33962341 DOI: 10.1016/j.bpc.2021.106608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Said MA, Albohy A, Abdelrahman MA, Ibrahim HS. Importance of glutamine 189 flexibility in SARS-CoV-2 main protease: Lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics. Eur J Pharm Sci 2021;160:105744. [PMID: 33540040 DOI: 10.1016/j.ejps.2021.105744] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Amendola G, Ettari R, Previti S, Di Chio C, Messere A, Di Maro S, Hammerschmidt SJ, Zimmer C, Zimmermann RA, Schirmeister T, Zappalà M, Cosconati S. Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening. J Chem Inf Model 2021;61:2062-73. [PMID: 33784094 DOI: 10.1021/acs.jcim.1c00184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
6 Shagufta, Ahmad I. The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. Eur J Med Chem 2021;213:113157. [PMID: 33486200 DOI: 10.1016/j.ejmech.2021.113157] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
7 Mehyar N, Mashhour A, Islam I, Alhadrami HA, Tolah AM, Alghanem B, Alkhaldi S, Somaie BA, Al Ghobain M, Alobaida Y, Alaskar AS, Boudjelal M. Discovery of Zafirlukast as a novel SARS-CoV-2 helicase inhibitor using in silico modelling and a FRET-based assay. SAR QSAR Environ Res 2021;32:963-83. [PMID: 34818959 DOI: 10.1080/1062936X.2021.1993995] [Reference Citation Analysis]
8 Banerjee S, Yadav S, Banerjee S, Fakayode SO, Parvathareddy J, Reichard W, Surendranathan S, Mahmud F, Whatcott R, Thammathong J, Meibohm B, Miller DD, Jonsson CB, Dubey KD. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study. J Chem Inf Model 2021;61:5469-83. [PMID: 34666487 DOI: 10.1021/acs.jcim.1c00524] [Reference Citation Analysis]
9 Chenchula S, Ray A, Sadasivam B. Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review. Drug Res (Stuttg) 2021;71:295-301. [DOI: 10.1055/a-1397-6763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chakraborty C, Bhattacharya M, Mallick B, Sharma AR, Lee SS, Agoramoorthy G. SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development. Expert Rev Clin Pharmacol 2021;14:225-38. [PMID: 33423554 DOI: 10.1080/17512433.2021.1874348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Tiwari V, Kumar M, Tiwari A, Sahoo BM, Singh S, Kumar S, Saharan R. Current trends in diagnosis and treatment strategies of COVID-19 infection. Environ Sci Pollut Res Int 2021;28:64987-5013. [PMID: 34601675 DOI: 10.1007/s11356-021-16715-z] [Reference Citation Analysis]
12 Oâ Donnell HR, Tummino TA, Bardine C, Craik CS, Shoichet BK. Colloidal aggregators in biochemical SARS-CoV-2 repurposing screens. bioRxiv 2021:2021. [PMID: 34494023 DOI: 10.1101/2021.08.31.458413] [Reference Citation Analysis]
13 Chen JM. Live unattenuated vaccines for controlling viral diseases, including COVID-19. J Med Virol 2021;93:1943-9. [PMID: 32833258 DOI: 10.1002/jmv.26453] [Reference Citation Analysis]
14 Agrawal PK, Agrawal C, Blunden G. Pharmacological Significance of Hesperidin and Hesperetin, Two Citrus Flavonoids, as Promising Antiviral Compounds for Prophylaxis Against and Combating COVID-19. Natural Product Communications 2021;16:1934578X2110425. [DOI: 10.1177/1934578x211042540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
15 Sasidharan S, Sarkar N, Saudagar P. Discovery of compounds inhibiting SARS-COV-2 multi-targets. J Biomol Struct Dyn 2022;:1-16. [PMID: 34994297 DOI: 10.1080/07391102.2021.2025149] [Reference Citation Analysis]
16 Arif A, Ansari S, Ahsan H, Mahmood R, Khan FH. An overview of Covid-19 pandemic: immunology and pharmacology. J Immunoassay Immunochem 2021;:1-20. [PMID: 33788668 DOI: 10.1080/15321819.2021.1904414] [Reference Citation Analysis]